
Valitse etikettisi
näkyy suoraan injektiopullossa2 laboratorioraporttia
PDF- Testattu
- Cagrilintide 10mg
- Laboratorio
- Analiza Białek
- Päivämäärä
- November 2026
- Tulos
- 99% purity (10.89 mg measured)
- Endotoksiinit
- 6.05 EU/vial
- Tilauksen nro
- Salasana
PDF- Testattu
- Cagrilintide 5mg
- Laboratorio
- Analiza Białek
- Päivämäärä
- August 2026
- Tulos
- 99% purity (5.11 mg measured)
- Endotoksiinit
- 3.93 EU/vial
- Tilauksen nro
- Salasana
Testattu riippumattomasti, tarkistettavissa salasanalla suoraan laboratoriossa.
Cagrilintide
Amylin
- Laboratoriotestattu · 99 % puhtaus
- Lähetetään Saksasta
Tilaus
- DHL seurannalla
- Huomaamaton pakkaus
4.6/5 Trustpilotissa73 arvostelua
Haettu myös nimellä: Cagrilintid · AM833
Yhdellä silmäyksellä
Cagrilintide lukuina
Tietopankkimme keskeiset luvut.
Koko tietopankkiartikkeli- Class
- Long-acting amylin analogue
- Frequency
- Once weekly
- Form
- Lyophilised powderreconstituted with BAC water
- Sizes
- 5 to 20 mg3 sizes in the shop
What studies show
All 2 sources in the lexiconArvostelut
Mitä asiakkaat sanovat
Vain todelliset tilaukset, joissa oli Cagrilintide.
Kaikki arvostelutTietoa
Kaikki aiheesta Cagrilintide
Tarkemmat tiedot tulossa pian.
Annostelu
Ladataan annostelutietoja …
Tilaa samalla
Mitä tarvitset sen kanssa
Bakteriostaattinen vesi lisätään ostoskoriisi automaattisesti. Ruiskut ja pyyhkeet yhdellä napsautuksella.
Insuliiniruiskut
10 kpl · 5.50 €
Alkoholipyyhkeet
50 kpl · 10 €
Kuinka paljon vettä?
Ruiskun yksiköt injektiopullosi koolle.
Avaa laskuri →Is cagrilintide approved?
No, according to ChEMBL there is no approval (as of 25 October 2026). ClinicalTrials.gov lists 21 phase 3 trials, ten of them completed. Most test the combination with semaglutide. Cagrilintide alone is being tested in phase 3 in the RENEW trials, with the primary endpoint planned for May 2027.
How does cagrilintide differ from GLP-1 compounds such as semaglutide?
The receptor. Cagrilintide binds to amylin and calcitonin receptors, not to the GLP-1 receptor. In rats it acted through specific nerve cells in the brainstem: when a signal there was switched off, the effect of cagrilintide disappeared but that of semaglutide did not. That is why the combination of the two is being studied.
What did the phase 2 trial show?
In the dose-finding trial with 706 participants weight fell by 6.0 to 10.8 percent after 26 weeks depending on the level, by 3.0 percent on placebo. At the highest level, 53 percent lost at least 10 percent according to the registry, on placebo 10 percent.
How long does cagrilintide stay in the body?
The half-life was 159 to 195 hours in a phase 1b study, so about seven days. That fits one dose a week, which is how the trials give it. With impaired kidney or liver function the level after a single dose was not meaningfully different.
What does the combination with semaglutide add?
In REDEFINE 1 weight fell by 20.4 percent on average after 68 weeks, by 3.0 percent on placebo. With type 2 diabetes (REDEFINE 2) it was 13.7 versus 3.4 percent. In a phase 2 trial in type 2 diabetes participants lost 15.6 percent in 32 weeks with the combination, 8.1 with cagrilintide alone and 5.1 percent with semaglutide alone.
Which side effects were seen?
Most often gastrointestinal effects, above all nausea: in the phase 2 trial 20 to 47 percent had it depending on the level, 18 percent on placebo. Constipation, injection site reactions and, at the highest level, more frequent fatigue came on top. The QT interval on the ECG did not lengthen relevantly in a dedicated study.
Which trials are still running?
Eleven phase 3 trials are not finished yet. The largest is REDEFINE 3 on cardiovascular events with 7,101 participants (primary endpoint planned for September 2027). For cagrilintide alone RENEW 1, 2 and 4 are running, plus a trial in children and adolescents until 2030.
Liittyvät
Samankaltaiset tuotteet
Cagrilintide